Biodegradable polymeric nanocarriers for pulmonary drug delivery

Expert Opinion on Drug Delivery

Volumn 5, Issue 6, 2008, Pages 629-639

  Rytting, Erik ^a   Nguyen, Juliane ^a   Wang, Xiaoying ^a   Kissel, Thomas ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Biodegradable polymers; Gene and siRNA delivery; Nanoparticles; Peptides; Proteins; Pulmonary drug delivery

Indexed keywords

ALBUMIN; ALGINIC ACID; CHITOSAN; COLLAGEN; CYCLODEXTRIN; DIPHTHERIA TOXOID; DNA VACCINE; EXCIPIENT; GELATIN; HYDROCHLORIC ACID; INSULIN; ISONIAZID; LACTOSE; MACROGOL; MANNITOL; MYCOBACTERIUM ANTIGEN; NANOCARRIER; POLY(ISOBUTYL 2 CYANOACRYLATE); POLYACRYLIC ACID; POLYANHYDRIDE; POLYETHYLENEIMINE; POLYGLACTIN; POLYLACTIDE; POLYMER; POLYVINYL ALCOHOL; PYRAZINAMIDE; RIFAMPICIN; SMALL INTERFERING RNA; TERBUTALINE SULFATE; UNINDEXED DRUG;

BIOCOMPATIBILITY; BIODEGRADABILITY; BRONCHIOLITIS; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONTROLLED DRUG RELEASE; DEGRADATION KINETICS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; DRUG TARGETING; DRUG TRANSPORT; ENCAPSULATION; GUINEA PIG; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LUNG ALVEOLUS MACROPHAGE; LUNG CARCINOMA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARTICLE SIZE; RESPIRATORY EPITHELIUM; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA INTERFERENCE; SPRAY DRYING; SURFACE CHARGE; SUSTAINED RELEASE FORMULATION; TUBERCULOSIS; VIRUS PNEUMONIA;

DNA; DRUG CARRIERS; LACTIC ACID; LUNG; NANOPARTICLES; POLYGLYCOLIC ACID; POLYMERS; PROTEINS; RNA, SMALL INTERFERING; VACCINES;

EID: 47349122617     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.6.629     Document Type: Review

References (82)

1. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur J Pharmacol 2006;533:341-50
2. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007;25:563-70
3. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006;58:1030-60
4. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006;58:996-1008
5. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 2006;58:1009-29
6. Steimer A, Haltner E, Lehr CM. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J Aerosol Med 2005;18:137-82
7. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007;6:67-74
8. Vyas SP, Khatri K. Liposome-based drug delivery to alveolar macrophages. Expert Opin Drug Deliv 2007;4:95-9
9. Jaspart S, Bertholet P, Piel G, et al. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm 2007;65:47-56
10. Xiang QY, Wang MT, Chen F, et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res 2007;30:519-25
11. Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Defiv Rev 2008; In press
12. Shi L, Plumley CJ, Berkland C. Biodegradable nanoparticle flocculates for dry powder aerosol formulation. Langmuir 2007;23:10897-901
13. Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res 2007;24:411-37
14. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55:329-47
15. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997;28:5-24
16. Lin SY, Chen KS, Teng HH, Li MJ. In vitro degradation and dissolution behaviours of microspheres prepared by three low molecular weight polyesters. J Microencapsul 2000;17:577-86
17. Berkland C, King M, Cox A, et al. Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release 2002;82:137-47
18. Yamamoto H, Kuno Y, Sugimoto S, et al. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005;102:373-81
19. Sanders LM, Kent JS, McRae GI, et al. Controlled release of a luteinizing hormone-releasing hormone analogue from poly(d,l-lactide-co-glycolide) microspheres. J Pharm Sci 1984;73:1294-7
20. Miyajima M, Koshika A, Okada J, Ikeda M. Effect of polymer/basic drug interactions on the two-stage diffusion-controlled release from a poly(L-lactic acid) matrix. J Control Release 1999;61:295-304
21. Youxin L, Kissel T. Synthesis and properties of biodegradable ABA triblock copolymers consisting of poly(-lactic acid) or poly (-lactic-co-glycolic acid) A-blocks attached to central poly (oxyethylene) B-blocks. J Control Release 1993;27:247-57
22. Kissel T, Li Y, Unger F. ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins. Adv Drug Deliv Rev 2002;54:99-134
23. Arvanitoyannis I, Nakayama A, Kawasaki N, Yamamoto N. Novel star-shaped polylactide with glycerol using stannous octoate or tetraphenyl tin as catalyst. 1. Synthesis, characterization and study of their biodegradability. Polymer 1995;36:2947-56
24. Kim SH, Han YK, Ahn KD, et al. Preparation of star-shaped polylactide with pentaerythritol and stannous octoate. Makromol Chem 1993;194:3229-36
25. Dong CM, Qiu KY, Gu ZW, Feng XD. Synthesis of star-shaped poly (d, l-lactic acid-alt-glycolic acid) with multifunctional initiator and SnOct2 catalyst. Polymer 2001;42:6891-6
26. Arvanitoyannis I, Nakayama A, Kawasaki N, Yamamoto N. Novel polylactides with aminopropanediol or aminohydroxymethylpropanediol using stannous octoate as catalyst-synthesis, characterization and study of their biodegradability. 2. Polymer 1995;36:2271-9
27. Breitenbach A, Kissel T. Biodegradable comb polyesters. Part 1. Synthesis, characterization and structural analysis of poly (lactide) and poly (lactide-co-glycolide) grafted onto water-soluble poly (vinyl alcohol) as backbone. Polymer 1998;39:3261-71
28. Youxin L, Nothnagel J, Kissel T. Biodegradable brush-like graft polymers from poly (d,l-lactide) or poly (d,l-lactide-co-glycolide) and charge-modified, hydrophilic dextrans as backbone - synthesis, characterization and in vitro degradation properties. Polymer 1997;38:6197-206
29. Oster CG, Wittmar M, Unger F, et al. Design of amine-modified graft polyesters for effective gene delivery using DNA-loaded nanoparticles. Pharm Res 2004;21:927-31
30. Simon M, Wittmar M, Bakowsky U, Kissel T. Self-assembling nanocomplexes from insulin and water-soluble branched polyesters, poly [(vinyl-3-(diethylamino)-propylcarbamate-co-(vinyl acetate)-co-(vinyl alcohol)]-graft-poly (l-lactic acid): a novel carrier for transmucosal delivery of peptides. Bioconjug Chem 2004;15:841-9
31. Jung T, Kamm W, Breitenbach A, et al. Loading of tetanus toxoid to biodegradable nanoparticles from branched poly (sulfobutyl-polyvinyl alcohol)-g-(lactide-co-glycolide) nanoparticles by protein adsorption: a mechanistic study. Pharm Res 2002;19:1105-13
32. Li Z, Huang L. Sustained delivery and expression of plasmid DNA based on biodegradable polyester, poly(,-lactide-co-4-hydroxy-proline). J Control Release 2004;98:437-46
33. Dailey LA, Wittmar M, Kissel T. The role of branched polyesters and their modifications in the development of modern drug delivery vehicles. J Control Release 2005;101:137-49
34. Breitenbach A, Pistel KF, Kissel T. Biodegradable comb polyesters. Part II. Erosion and release properties of poly(vinyl alcohol)-g-poly(lactic-co-glycolic acid). Polymer 2000;41:4781-92
35. Frauke Pistel K, Breitenbach A, Zange-Volland R, Kissel T. Brush-like branched biodegradable polyesters, part III: Protein release from microspheres of poly(vinyl alcohol)-graft-poly (,-lactic-co-glycolic acid). J Control Release 2001;73:7-20
36. Yamaoka T, Tabata Y, Ikada Y. Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration. J Pharm Pharmacol 1995;47:479-86
37. Breitenbach A, Li YX, Kissel T. Branched biodegradable polyesters for parenteral drug delivery systems. J Control Release 2000;64:167-78
38. Li Y, Nothnagel J, Kissel T. Biodegradable brush-like graft polymers from poly(-lactide) or poly(-lactide-co-glycolide) and charge-modified, hydrophilic dextrans as backbone - synthesis, characterization and in vitro degradation properties. Polymer 1997;38:6197-206
39. Li Y, Volland C, Kissel T. Biodegradable brush-like graft polymers from poly(D,L-lactide) or poly(D,L-lactide-coglycolide) and charge-modified, hydrophilic dextrans as backbone - in vitro degradation and controlled releases of hydrophilic macromolecules. Polymer 1998;39:3087-97
40. Jung T, Breitenbach A, Kissel T. Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres. J Control Release 2000;67:157-69
41. Dailey LA, Jekel N, Fink L, et al. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 2006;215:100-8
42. Dailey LA, Kleemann E, Wittmar M, et al. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm Res 2003;20:2011-20
43. Shoyele SA, Slowey A. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int J Pharm 2006;314:1-8
44. Kissel T, Wang XY. Graft copolymers as drug delivery systems. EP07116143; 2007
45. Wang X, Xie X, Cai C, et al. Biodegradable branched polyesters poly(vinyl sulfonate-co-vinyl alcohol)-graft-P(D,L-lactic-co-glycolic acid) as negatively-charged polyelectrolyte platforms for drug delivery: synthesis and characterization. Macromolecules 2008;41:2791-9
46. Fiegel J, Fu J, Hanes J. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J Control Release 2004;96:411-23
47. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm 2001;218:75-80
48. Sanders LM, Kell BA, McRae GI, Whitehead GW. Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer. J Pharm Sci 1986;75:356-60
49. Zolnik BS, Burgess DJ. Effect of acidic PH on PLGA microsphere degradation and release. J Control Release 2007;122:338-44
50. Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother 2001;47:829-35
51. Dutt M, Khuller GK. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Int J Antimicrob Agents 2001;17:115-22
52. Lu D, Garcia-Contreras L, Xu D, et al. Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm Res 2007;24:1834-43
53. Garcia-Contreras L, Sethuraman V, Kazantseva M, et al. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J Antimicrob Chemother 2006;58:980-6
54. Pandey R, Sharma A, Zahoor A, et al. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-6
55. Lee KY, Ha WS, Park WH. Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. Biomaterials 1995;16:1211-6
56. Varum KM, Myhr MM, Hjerde RJ, Smidsrod O. In vitro degradation rates of partially N-acetylated chitosans in human serum. Carbohydr Res 1997;299:99-101
57. Tomihata K, Ikada Y. In vitro and in vivo degradation of film of chitin and its deacetylated derivatives. Biomaterials 1997;18:567-75
58. Nicod LP. Lung defences: an overview. Eur Respir Rev 2005;14:45-50
59. Skerrett SJ. Lysozyme in pulmonary host defense: new tricks for an old dog. Am J Respir Crit Care Med 2004;169:435-6
60. Learoyd TP, Burrows JL, French E, Seville PC. Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm 2008;68:224-34
61. Corrigan DO, Healy AM, Corrigan OI. Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates. Eur J Pharm Biopharm 2006;62:295-305
62. Amidi M, Pellikaan HC, de Boer AH, et al. Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery. Eur J Pharm Biopharm 2008;68:191-200
63. Grenha A, Seijo B, Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005;25:427-37
64. Kawashima Y, Yamamoto H, Takeuchi H, et al. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release 1999;62:279-87
65. Lungwitz U, Breunig M, Blunk T, Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 2005;60:247-66
66. Zou SM, Erbacher P, Remy JS, Behr JP. Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse. J Gene Med 2000;2:128-34
67. Thomas M, Lu JJ, Zhang C, et al. Identification of novel superior polycationic vectors for gene delivery by high-throughput synthesis and screening of a combinatorial library. Pharm Res 2007;24:1564-71
68. Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114:100-9
69. Germershaus O, Mao S, Sitterberg J, et al. Gene delivery using chitosan, trimethyl chitosan or polyethylenglycol-graft-trimethyl chitosan block copolymers: establishment of structure-activity relationships in vitro. J Control Release 2008;125:145-54
70. MacLaughlin FC, Mumper RJ, Wang J, et al. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release 1998;56:259-72
71. Koping-Hoggard M, Tubulekas I, Guan H, et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther 2001;8:1108-21
72. Koping-Hoggard M, Varum KM, Issa M, et al. Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther 2004;11:1441-52
73. Issa MM, Koping-Hoggard M, Tommeraas K, et al. Targeted gene delivery with trisaccharide-substituted chitosan oligomers in vitro and after lung administration in vivo. J Control Release 2006;115:103-12
74. Fajac I, Briand P, Monsigny M, Midoux P. Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells. Hum Gene Ther 1999;10:395-406
75. Weis WI, Drickamer K. Structural basis of lectin-carbohydrate recognition. Ann Rev Biochem 1996;65:441-73
76. Andersen MO, Howard KA, Paludan SR, et al. Delivery of siRNA from lyophilized polymeric surfaces. Biomaterials 2008;29:506-12
77. Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006;14:476-84
78. Kong X, Zhang W, Lockey RF, et al. Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet Vaccines Ther 2007;5:4
79. Palese P, Garcia-Sastre A. Influenza vaccines: present and future. J Clin Invest 2002;110:9-13
80. Orme IM, McMurray DN, Belisle JT. Tuberculosis vaccine development: recent progress. Trends Microbiol 2001;9:115-8
81. Bivas-Benita M, Ottenhoff THM, Junginger HE, Borchard G. Pulmonary DNA vaccination: Concepts, possibilities and perspectives. J Control Release 2005;107:1-29
82. Bivas-Benita M, Romeijn S, Junginger HE, Borchard G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm Biopharm 2004;58:1-6